Time and cost of administering COVID-19 mRNA vaccines in the United States
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly developed. A thorough understanding of the diffe...
Saved in:
Main Authors: | Benjamin Yarnoff (Author), Steven Bodhaine (Author), Ed Cohen (Author), Philip O. Buck (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mRNA as a Therapeutics: Understanding mRNA Vaccines
by: Ferdi Oğuz, et al.
Published: (2022) -
Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024) -
SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
by: Mitsuhito Ota, MD, PhD
Published: (2022) -
The potential of mRNA vaccine in HCC treatment
by: Rui Han
Published: (2023) -
Commentary of the mRNA vaccines COVID-19
by: Antonio Vitiello, et al.
Published: (2021)